



(51) International Patent Classification:

C07K 16/24 (2006.01) A61P 17/00 (2006.01)
A61P 11/06 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2024/043747

(22) International Filing Date:

23 August 2024 (23.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/578,947 25 August 2023 (25.08.2023) US

(71) Applicant: **PROTEOLOGIX US INC.** [US/US]: 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US).

(72) Inventors: **WANG, Yan**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US). **TANG, Jie**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US). **ZHENG, Yan**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US). **CRAWFORD, Yongping**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US). **TANG, Danming**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US). **ZHANG, Rui**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US). **SHEN, Wenyan**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, California 94065 (US).

(74) Agent: **COHEN, Adrienne O.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: ANTI-TSLP ANTIBODY CONSTRUCTS AND USES THEREOF

FIG. 1

TSLP reporter assay with 10 ng/mL TSLP



(57) Abstract: The present invention relates to isolated antibody constructs that specifically recognize TSLP. Compositions, kits, methods of making, and methods of use (e.g., treating inflammatory disease) are also provided.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*